convulsions epileptic seizures
Conditions
Interventions
Levetiracetam intravenously as a second or third line anticonvulsant, 20 mg/kg
in the absence of a response after 10 min. a second dose of 20 mg/kg will be
given.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: ·newborn gestational age >= 37 weeks, birth weight > 1500 grams ·refractory to phenobarbitone up to 40 mg/kg or refractory to phenobarbitone up to 40 mg/kg and midazolam up to 0.5 mg/kg (raised from 0.1 mg/kg every 10-15 minutes when effect fails) ·after correction or treatment of metabolic causes as inborn errors, hypoglycemia or hypocalcaemia or CNS infections
Exclusion criteria
Exclusion criteria: ·newborn gestational age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety profile of LEV in neonates. Outcome parameters as liver-, kidney- and metabolic function, electrolytes, hemodynamic effects (heart rate/arrythmias, arterial bloodpressure/hypotension). Investigation of pharmacokinetic and - dynamic properties of LEV at neonates. | — |
Secondary
| Measure | Time frame |
|---|---|
| Increase of epileptic seizures and medication interaction will be measured. | — |
Countries
Netherlands
Outcome results
None listed